Endogenous tissue-type plasminogen activator and risk of myocardial infarction

作者: Paul M Ridker , Douglas E Vaughan , Je Manson , CH Hennekens , Mj Stampfer

DOI: 10.1016/0140-6736(93)90998-V

关键词:

摘要: Abstract Endogenous tissue-type plasminogen activator (tPA) has been hypothesised to be a marker of baseline fibrinolytic capacity. We therefore tested whether tPA antigen is associated with the occurrence future myocardial infarction (Ml) among apparently healthy individuals. concentrations were measured at in plasma samples from 231 men Physicians' Health Study cohort who later developed Ml, and an equal number controls matched for age smoking habit remained free reported cardiovascular disease during follow-up 60·2 months. In crude matched-pair analyses, higher cases than (p=0·03) strongly risk Ml. Specifically, relative risks developing first Ml lowest (referent) highest quintiles 1·00, 1·27, 1·75, 1·88, 2·81 (p trend 0·0008, 95% Cl fifth as compared quintile 1·47 5·37, p=0·002). Analyses which adjusted factors that affect progression atherosclerosis, particularly HDL-cholesterol, abolished statistical significance this association, finding suggests elevations are result rather cause atherosclerotic coronary disease. These prospective data suggest endogenous increase consequence important preclinical atherosclerosis may

参考文章(22)
ED Sprengers, C Kluft, Plasminogen activator inhibitors. Blood. ,vol. 69, pp. 381- 387 ,(1987) , 10.1182/BLOOD.V69.2.381.BLOODJOURNAL692381
Björn Wiman, Anders Hamsten, Impaired fibrinolysis and risk of thromboembolism. Progress in Cardiovascular Diseases. ,vol. 34, pp. 179- 192 ,(1991) , 10.1016/0033-0620(91)90012-B
J Aznar, A Estelles, G Tormo, P Sapena, V Tormo, S Blanch, F Espana, Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Heart. ,vol. 59, pp. 535- 541 ,(1988) , 10.1136/HRT.59.5.535
Y Vandekerckhove, G Baele, H De Puydt, A Weyne, D Clement, Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thrombosis Research. ,vol. 50, pp. 449- 453 ,(1988) , 10.1016/0049-3848(88)90274-5
Jawahar Mehta, Paulette Mehta, Daniel Lawson, Tom Saldeen, Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations Journal of the American College of Cardiology. ,vol. 9, pp. 263- 268 ,(1987) , 10.1016/S0735-1097(87)80373-X
Paul M Ridker, Douglas E Vaughan, Meir J Stampfer, Joann E Manson, Caifang Shen, Laura M Newcomer, Samuel Z Goldhaber, Charles H Hennekens, None, Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. ,vol. 85, pp. 1822- 1827 ,(1992) , 10.1161/01.CIR.85.5.1822
Anders Hamsten, Göran Walldius, Alfred Szamosi, Margareta Blombäck, UlfDe Faire, Gösta Dahlén, Christian Landou, Björn Wiman, PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION The Lancet. ,vol. 330, pp. 3- 9 ,(1987) , 10.1016/S0140-6736(87)93050-9
I.D. Walker, J.F. Davidson, I. Hutton, T.D.V. Lawrie, Disordered “fibrinolytic potential” in coronary heart disease Thrombosis Research. ,vol. 10, pp. 509- 520 ,(1977) , 10.1016/0049-3848(77)90160-8
Paul M Ridker, None, An epidemiologic assessment of thrombotic risk factors for cardiovascular disease Current Opinion in Lipidology. ,vol. 3, pp. 285- 290 ,(1992) , 10.1097/00041433-199208000-00007